Foghorn Therapeutics
FHTX
81 hedge funds and large institutions have $193M invested in Foghorn Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 17 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
31% more capital invested
Capital invested by funds: $148M → $193M (+$45M)
0.8% more ownership
Funds ownership: 72.69% → 73.49% (+0.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
10% less funds holding
Funds holding: 90 → 81 (-9)
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$975K |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$627K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$622K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$489K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$469K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RWM
Rockwood Wealth Management
New Hope,
Pennsylvania
|
-$392K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$227K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$205K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$187K |
| 5 |
State Street
Boston,
Massachusetts
|
-$178K |
FHTX Hedge Fund Activity: Q2 2025 in Review
81 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2025, worth a combined $193M — up 31% from $148M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of FHTX and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 37 added.
The largest buyer was BlackRock, adding an estimated $975K. The largest seller was Rockwood Wealth Management, exiting entirely with an estimated $392K sold.
- 81 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2025, down from 90 in Q1 2025.
- Funds reported $193M of Foghorn Therapeutics stock for Q2 2025, up 31% quarter-over-quarter.
- 8 funds opened new Foghorn Therapeutics positions in Q2 2025 and 17 closed out, a net change of -9 holders.
- The largest Foghorn Therapeutics buyer in Q2 2025 was BlackRock, an estimated $975K added.
- The largest Foghorn Therapeutics seller in Q2 2025 was Rockwood Wealth Management, an estimated $392K sold.
Based on aggregated 13F filings for Q2 2025.